JOINN(SH:603127) Xin Lang Cai Jing·2025-04-10 02:39Group 1 - The Hong Kong innovative drug index (987018) has seen a strong increase of 4.76% as of April 10, 2025, with notable gains in constituent stocks such as WuXi AppTec (02268) up 15.21%, and others like 3SBio (01530) and Zai Lab (06127) also showing significant increases [1] - The Hong Kong innovative drug ETF (159567) rose by 8.10%, reaching a latest price of 1.14 yuan, and has accumulated a 14.88% increase over the past three months, ranking in the top third among comparable funds [1] - The trading activity for the Hong Kong innovative drug ETF is robust, with a turnover rate of 46.38% and a transaction volume of 400 million yuan, indicating active market participation [1] Group 2 - The innovative drug market in China is experiencing rapid development driven by policy support, with significant market potential and opportunities for investment in globally competitive products [2] - The optimization of medical insurance policies and the introduction of the innovative drug category are expected to improve market access and payment environments, thereby boosting market demand [2] - Chinese innovative drug companies are actively expanding into overseas markets, presenting a broad outlook for growth, while the demand for medical equipment upgrades and increased policy support may lead to a turning point for enterprises [2]